Thursday Feb 27
Eisai Inc. Announces Initiation Of A Phase 3 Trial Of Eribulin...
Eisai Inc. Announces Initiation Of A Phase 3 Trial Of Eribulin Mesylate Injection Versus Weekly Paclitaxel In First And Second Lines Of Metastatic Breast Cancer /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel ... (more)
Thursday Feb 27
ACCRU Launches Trial Comparing Eribulin to Paclitaxel for Recurrent or Metastatic Breast Cancer
Academic and Community Cancer Research United today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 negative, locally recurrent, unresectable or metastatic breast ... (more)
Arena Pharmaceuticals, Inc. Announces Filing For Marketing...
In connection with the filing, Arena will receive a milestone payment of being overweight or obese, there is a significant need for new chronic weight management treatments to help address this medical need," said Jack Lief, Arena's President and Chief Executive Officer.
Eisai Inc. Reports Improved Patient Access For BELVIQ (lorcaserin HCI) CIV
CVS Caremark customers have broadened the coverage of Eisai's BELVIQ, according to Fingertip Formulary, an integrated database of formulary information.
Phase 3 Trial Shows Lenvatinib Meets Primary Endpoint of Progression...
Eisai Inc. announced today that the Phase 3 SELECT trial of investigational agent lenvatinib met its primary endpoint.